Agency

Under Secretary Cravins Announces Formation of MBDA Minority Business Enterprise Advisory Council

Retrieved on: 
Friday, January 12, 2024

WASHINGTON, Jan. 12, 2024 /PRNewswire/ -- Today, Donald R. Cravins, Jr., Under Secretary of Commerce for Minority Business Development, announced the formation of the U.S. Department of Commerce, Minority Business Development Agency's (MBDA) Minority Business Enterprise Advisory Council.

Key Points: 
  • WASHINGTON, Jan. 12, 2024 /PRNewswire/ -- Today, Donald R. Cravins, Jr., Under Secretary of Commerce for Minority Business Development, announced the formation of the U.S. Department of Commerce, Minority Business Development Agency's (MBDA) Minority Business Enterprise Advisory Council.
  • As stated in The Minority Business Development Act of 2021, this council will advise and assist MBDA in their mission to promote the growth of minority owned businesses.
  • "The Minority Business Enterprise Advisory Council is a critical lever of MBDA's role as a leading authority for minority and underserved businesses," said Under Secretary Cravins.
  • The Council is composed of nine private sector members and one representative from each of ten Federal agencies that support business formation, labor development, monetary policy, national security, energy, agriculture, transportation, and housing.

A UNIVERSAL CORONAVIRUS VACCINE COULD SAVE BILLIONS OF DOLLARS IF READY BEFORE NEXT PANDEMIC

Retrieved on: 
Thursday, January 11, 2024

NEW YORK, Jan. 11, 2024 /PRNewswire/ -- What if scientists had developed a universal coronavirus vaccine in the years prior to 2020 so that it was available at the start of the COVID-19 pandemic? A universal coronavirus vaccine targets parts of the virus that are common to either many or all coronaviruses, thereby offering some degree of protection against a range of strains. A new study suggests if such a vaccine were available at the start of the pandemic, it could have saved millions of lives, prevented suffering, and saved billions of dollars in direct medical and other costs until the strain-specific (i.e., SARS-CoV-2) vaccine went through the entire development, testing, and emergency use authorization process that lasted 10 months.

Key Points: 
  • NEW YORK, Jan. 11, 2024 /PRNewswire/ -- What if scientists had developed a universal coronavirus vaccine in the years prior to 2020 so that it was available at the start of the COVID-19 pandemic?
  • A universal coronavirus vaccine targets parts of the virus that are common to either many or all coronaviruses, thereby offering some degree of protection against a range of strains.
  • The experiments simulated what would happen if a universal coronavirus vaccine was available at the start of the COVID-19 pandemic.
  • A universal coronavirus vaccine was also shown to be highly cost-effective even if a more specific and more efficacious vaccine came to market.

Government of Canada invests in developing a portable test for domoic acid, a marine biotoxin

Retrieved on: 
Wednesday, January 10, 2024

This and other marine biotoxins are of particular interest to communities with a greater reliance on fish and seafood in their diets.

Key Points: 
  • This and other marine biotoxins are of particular interest to communities with a greater reliance on fish and seafood in their diets.
  • Eating shellfish with high levels of marine biotoxins, including domoic acid, can cause severe food poisoning and life-threatening neurological effects.
  • This type of portable test would be used to detect even the lowest levels of domoic acid in marine waters in real time.
  • Research and development on a portable test for domoic acid can help advance our understanding of the relationship between this marine biotoxin and environmental conditions."

Trident Air to preview upcoming wall-mountable interlocking air purifier at CES 2024

Retrieved on: 
Tuesday, January 9, 2024

LAS VEGAS, Jan. 9, 2024 /PRNewswire-PRWeb/ -- Today, Trident Air, a leader in innovative air purification solutions, is excited to announce its participation in the 2024 Consumer Electronics Show (CES). The brand will be exhibiting in Vegas at The Venetian Expo Hall G, Eureka Park, booth 61613 from January 9 - 12, 2024, offering an exclusive sneak peek of its upcoming HEX wall-mountable and interlocking air purifier, alongside its bestselling Hunter and Bliss models.

Key Points: 
  • HEX features the brand's proprietary Air Dome Technology, which disinfects air and surfaces in minutes
    LAS VEGAS, Jan. 9, 2024 /PRNewswire-PRWeb/ -- Today, Trident Air , a leader in innovative air purification solutions, is excited to announce its participation in the 2024 Consumer Electronics Show (CES).
  • HEX, due to launch in Q1 2024, is the slimmest and lightest of Trident Air's purifiers.
  • "Our Air Dome Technology mimics the germicidal properties of outdoor air," said Dr. Ivan Tan, Trident Air Co-founder and Principal Scientist.
  • Trident Air is excited to preview the HEX, which is still in development, at CES 2024.

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Retrieved on: 
Monday, January 8, 2024

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Retrieved on: 
Monday, January 8, 2024

Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Retrieved on: 
Saturday, January 6, 2024

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Herbal medicinal product: Sideritis herbaArray,Array,Array,Array, F: Assessment finalised

Retrieved on: 
Friday, January 5, 2024

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of ironwort.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing ironwort.
  • Ironwort is the common name for the aerial parts of various species of Sideritis plants (which include Sideritis scardica Griseb.
  • Ironwort preparations may also be found in combination with other herbal substances in some herbal medicines.

Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Friday, January 5, 2024

BRIDGEWATER, N.J., Jan. 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the Company's four pillars and outlook for 2024. These updates will be discussed as part of the Company's presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 8, 2024, at 3:00 p.m. PT (6:00 p.m. ET).

Key Points: 
  • Insmed received encouraging written feedback from the U.S. Food and Drug Administration (FDA) on the patient-reported outcome data produced in the Phase 3 ARISE study in December 2023.
  • Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
    Will Lewis, Chair and Chief Executive Officer of Insmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 p.m. PT (6:00 p.m.
  • A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at www.insmed.com .
  • A replay will also be archived for a period of 30 days following the conclusion of the live event.